Novel AI blood test detects liver cancer

A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected more than 80% of liver cancers in a new study of 724 people. The blood test, called DELFI (DNA evaluation of fragments for early interception) detects fragmentation changes among DNA from […]

Researchers develop optical biopsy system that detects liver cancer

New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and healthy liver tissue. The new technology could make it easier to diagnose liver cancer, which is the sixth most common cancer globally. “The instrument is designed to be compatible with the needles […]

Study introduces new strategy to treat advanced liver cancer

Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by combining systemic immunotherapy with internal radiation therapy Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis A recent study introduces a new approach to treat advanced […]

External-beam radiation therapy underused for people with liver cancer awaiting transplant

First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from non-invasive radiation treatments but are rarely given this therapy, according to a new analysis of U.S. national data. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. […]

Phase III KEYNOTE-394 trial of Keytruda meets primary endpoint in hepatocellular carcinoma – Merck Inc

Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met its primary endpoint of overall survival (OS). The study found that treatment with Keytruda plus best supportive care resulted in a statistically significant improvement in OS compared with placebo plus best supportive […]